Affordable Access

deepdyve-link
Publisher Website

Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT.

Authors
  • Herr, Andrée-Laure
  • Kabbara, Nabil
  • Bonfim, Carmem M S
  • Teira, Pierre
  • Locatelli, Franco
  • Tiedemann, Karin
  • Lankester, Arjan
  • Jouet, Jean-Pierre
  • Messina, Chiara
  • Bertrand, Yves
  • Díaz de Heredia, Cristina
  • Peters, Christina
  • Chaves, Wagnara
  • Nabhan, Samir K
  • Ionescu, Irina
  • Gluckman, Eliane
  • Rocha, Vanderson
Type
Published Article
Journal
Blood
Publisher
American Society of Hematology
Publication Date
Sep 16, 2010
Volume
116
Issue
11
Pages
1849–1856
Identifiers
DOI: 10.1182/blood-2010-02-271692
PMID: 20538797
Source
Medline
License
Unknown

Abstract

We analyzed risk factors influencing outcomes after related (R) human leukocyte antigen-identical cord blood transplantation (CBT) for 147 patients with malignancies reported to Eurocord-European Group for Blood and Marrow Transplantation. CBT has been performed since 1990; median follow-up was 6.7 years. Median patient age was 5 years. Acute leukemia was the most frequent diagnosis (74%). At CBT, 40 patients had early, 70 intermediate, and 37 advanced disease. CB grafts contained a median of 4.1 × 10(7)/kg total nucleated cells (TNCs) after thawing. The cumulative incidence (CI) of neutrophil recovery was 90% at day +60. CIs of acute and chronic graft-versus-host disease (GVHD) were 12% and 10% at 2 years, respectively. At 5 years, CIs of nonrelapse mortality and relapse were 9% and 47%, respectively; the probability of disease-free survival (DFS) and overall survival were 44% and 55%, respectively. Among other factors, higher TNCs infused was associated with rapid neutrophil recovery and improved DFS. The use of methotrexate as GVHD prophylaxis decreased the CI of engraftment. Patients without advanced disease had improved DFS. These results support banking and use of CB units for RCBT. Cell dose, GVHD prophylaxis not including methotrexate, and disease status are important factors for outcomes after RCBT.

Report this publication

Statistics

Seen <100 times